Results 21 to 30 of about 12,722 (192)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Journal of Cardiovascular Development and Disease, 2022
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the ...
Hisham A. Badreldin, Nasser Aldosari, Lama Alnashwan, Taif Almutairi, Nada Yousif, Khalid Alsulaiman, Ohoud Aljuhani, Awatif Hafiz, Omar Alshaya   +8 more
doaj   +1 more source

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene, Sujung Choi, Steven J. Lippmann, Robert J. Mentz, Melissa A. Greiner, N. Chantelle Hardy, Bradley G. Hammill, Nancy Luo, Marc D. Samsky, Paul A. Heidenreich, Warren K. Laskey, Clyde W. Yancy, Pamela N. Peterson, Lesley H. Curtis, Adrian F. Hernandez, Gregg C. Fonarow, Emily C. O'Brien   +16 more
doaj   +1 more source

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation

Frontiers in Cardiovascular Medicine, 2022
BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen, Yunlin Chen, Fang Qin, Huaan Du, Chunxia Gan, Bei Zhou, Na Wang, Mingyang Xiao, Zhenhong Ou, Wei Zhao, Ben Cui, Zengzhang Liu, Yuehui Yin   +12 more
doaj   +1 more source

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data [PDF]

, 2016
BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the ...
Baigent, C., Baxter, A., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., Dayanandan, R., Emberson, J., Haynes, R., Herrington, W.G., Hill, M., Judge, P.K., Kalra, P.A., Knott, C., Landray, M.J., McMurray, John J., Murphy, K., Roderick, P., Staplin, N., Storey, B.C., Taal, M., Tomson, C., Wheatley, K., Wheeler, D.C.   +23 more
core   +4 more sources

Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats

Frontiers in Pharmacology, 2022
Clinical use of the combination therapy of the neprilysin inhibitor sacubitril and angiotensin II type 1 receptor blocker valsartan is known to be associated with albuminuria.
Elizabeth Alana Gray, Sanket N. Patel, Peter A. Doris, Tahir Hussain   +3 more
doaj   +1 more source

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2022
BackgroundSacubitril/valsartan therapy reduced the risks of death and of hospitalization for heart failure (HF). HF and cardiac arrhythmias have shared physiological mechanisems.
Xue-Hui Liu, Xue-Hui Liu, Guan-Ling Wang, Qiang Xu, Qiang Xu, Lei Zhang, Lei Zhang, Hong-Jun Liu, Hong-Jun Liu   +8 more
doaj   +1 more source

Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2022
ObjectiveHeart failure (HF) and atrial fibrillation (AF) are often coexisting. They have common risk factors and pathophysiologic mechanisms. Sacubitril/valsartan has shown efficacy and tolerability in patients with HF.
Xuehui Liu, Hongjun Liu, Lijun Wang, Lei Zhang, Qiang Xu   +4 more
doaj   +2 more sources

Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]

, 2017
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella, Triposkiadis, Filippos   +1 more
core   +2 more sources

Combined Angiotensin Receptor–Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundThere is a paucity of data about the mechanisms by which sacubitril/valsartan (also known as LCZ696) improves outcomes in patients with heart failure. Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability
Rishi K. Trivedi, David J. Polhemus, Zhen Li, Daniel Yoo, Hiroshi Koiwaya, Amy Scarborough, Traci T. Goodchild, David J. Lefer   +7 more
doaj   +1 more source

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Aims: In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment.
Koichiro Matsumura MD, Takeshi Ijichi MD, Junko Morimoto MD, Kensuke Takabayashi MD, Mitsunori Miho MD, Keisuke Ueno MD, Eijiro Yagi MD, Toru Takase MD, Masafumi Ueno MD, Gaku Nakazawa MD   +9 more
doaj   +1 more source